MRT-Leberdiagnostik mit dem leberspezifischen Kontrastmittel Gd-EOB-DTPA

In a Phase III clinical trial the liver-specific MRI contrast agent Gd-EOB-DTPA was administered to 40 Patients. The substance showed very good tolerance. After intravenous bolus injection a non-specific vascular phase can be performed. After that liver-specific imaging is possible. Sensitivity and specificity in unenhanced MRI were 83% and 100% and could be increased to 91% and 98% by Gd-EOB-DTPA administration. Sensitivity and specificity in contrast-enhanced spiral-CT were 73% and 100%. Characterization rate could be increased from 92% in the unenhanced scans to 99% after Gd-EOB-DTPA administration. Biphasic spiral-CT showed a correct characterization rate of 93%. Quantitative assessment showed an increase of information content in the post-contrast scans due to a siginificant increase of liver-lesion contrast. Increased contrast-to-noise values are helpful to perform correct characterization. Gd-EOB-DTPA enhanced MRI of the liver is superior in detection and characterization of focal liver lesions to both unenhanced MRI and contrast-enhanced spiral-CT. Vascular and liver-specific imaging can be performed within one examination. This allows better treatment planning and higher efficiency in scanner utilization.

Level thesis:degree_level

thesis.doctoral

Grantor dc:publisher

Ludwig-Maximilians-Universität

Year

2003

Author dc:creator

• Kraus, Armin

Repository record source_url

https://edoc.ub.uni-muenchen.de/1275/

OAI identifier oai:identifier

oai:edoc.ub.uni-muenchen.de:1275